Recommendations for follow-up care of individuals with an inherited predisposition to cancer: II. BRCA1 and BRCA2

JAMA

Volumn 277, Issue 12, 1997, Pages 997-1003

  Burke, Wylie ^a,l   Daly, Mary ^b   Garber, Judy ^c   Botkin, Jeffrey ^d   Kahn, Mary Jo Ellis ^e   Lynch, Patrick ^f   McTiernan, Anne ^g   Offit, Kenneth ^h   Perlman, Jeffrey ⁱ   Petersen, Gloria ^j   Thomson, Elizabeth ^k   Varricchio, Claudette ⁱ  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e National Breast Cancer Coalition   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g USA   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j JOHNS HOPKINS UNIVERSITY   (United States)

^k NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^l UNIVERSITY OF WASHINGTON   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; ESTROGEN; ORAL CONTRACEPTIVE AGENT; PROSTATE SPECIFIC ANTIGEN; TAMOXIFEN; TUMOR MARKER;

ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; COLORECTAL CANCER; ECHOGRAPHY; ESTROGEN THERAPY; FOLLOW UP; GENE MUTATION; HUMAN; LIFESTYLE; MAMMOGRAPHY; MASTECTOMY; OCCULT BLOOD TEST; OVARIECTOMY; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; SIGMOIDOSCOPY; THROMBOSIS;

EID: 0030893779     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.277.12.997     Document Type: Article

References (120)

1. Easton DF, Ford D, Bishop DT, and the Breast Cancer Linkage Consortium. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet. 1995;56:265-271.
2. Ford D, Easton DF. The genetics of breast and ovarian cancer. Br J Cancer. 1995;72:805-812.
3. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE, and the Breast Cancer Linkage Consortium. Risks of cancer in BRCA1-mutation carriers. Lancet. 1994;343:692-695.
4. Easton DF, Bishop DT, Ford D, Crockford GP, and the Breast Cancer Linkage Consortium. Genetic linkage analysis in familial breast and ovarian cancer. Am J Hum Genet. 1993;52:678-701.
5. Biesecker BB, Boehnke M, Calzone K, et al. Genetic counseling for families with inherited susceptibility to breast and ovarian cancer. JAMA. 1993; 269:1970-1974.
6. King M-C, Rowell S, Love SM. Inherited breast and ovarian cancer. JAMA. 1993;269:1975-1980.
7. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66-71.
8. Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2,to chromosome 13q12-13. Science. 1994;265: 2088-2090.
9. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:789-791.
10. US Preventive Services Task Force. Guide to Clinical Preventive Services. 2nd ed. Baltimore, Md: Williams & Wilkins; 1996.
11. Burke W, Petersen G, Lynch P, et al, for the Cancer Genetics Studies Consortium. Recommendations for follow-up care of individuals with an inherited predisposition to cancer, I: hereditary non-polyposis colon cancer. JAMA. 1997;277:915-919.
12. Neuhasen SL, Mazoyer S, Friedman L, et al. Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. Am J Hum Genet. 1996;58:271-280.
13. Phelan CM, Rebbeck TR, et al. Ovarian cancer risk in BRCA1 carriers is modified by HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet. 1996;12:309-311.
14. Tavtigian SV, Simard J, Rommens J, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet. 1996;12:10-14.
15. Thorlacius S, Tryggvadottir L, Olafsdottir GH, et al. Linkage to BRCA2 region in hereditary male cancer. Lancet. 1995;345:544-545.
16. Gudmundsson J, Johannesdottir G, Bergthorsson JT, et al. Different tumor types from BRCA2. carriers show wild-type chromosome deletions on 13q12-q13. Cancer Res. 1995;55:4830-4832.
17. Shattuck-Eidens D, McClure M, Simard J, et al. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. JAMA. 1995;273:535-541.
18. Claus EB, Risch N, Thompson WB. Autosomal dominant inheritance of early onset breast cancer. Cancer. 1994;73:643-651.
19. Foster RS Jr, Lang SP, Costanza MC, Worden JK, Haines CR, Yates JW. Breast self-examination practices and breast-cancer stage. N Engl J Med. 1978;299:265-270.
20. Greenwald P, Nasca PC, Lawrence CE, et al. Estimated effect of breast self-examination and routine physician examinations on breast-cancer mortality. N Engl J Med. 1978;299:271-273.
21. Newcomb P, Weiss N, Storer B, et al. Breast self-examination in relation to the occurrence of advanced breast cancer. J Natl Cancer Inst. 1991; 83:260-265.
22. Thomas DB, Gao DL, Self S, et al. A randomized trial of breast self-examination in Shanghai: methodology and preliminary results. J Natl Cancer Inst. In press.
23. Beam CA, Layde PM, Sullivan DC. Variability in the interpretation of screening mammograms by US radiologists. Arch Intern Med. 1996;156:209-213.
24. Burhenne HJ, Burhenne LW, Goldberg F, et al. Interval breast cancers in the screening program of British Columbia: analysis and classification. AJR Am J Roentgenol. 1994;162:1067-1071.
25. Kopans DB. Interval breast cancers in the screening mammography program of British Columbia: analysis and classification. AJR Am J Roentgenol. 1995;164:1298-1299.
26. Fletcher S, O'Malley MS, Earp JL, Morgan TM, Lin S, Degnan D. How best to teach women breast self-examination: a randomized controlled trial. Ann Intern Med. 1990;112:772-779.
27. Bennett SE, Lawrence RS, Fleischmann KH, Gifford CS, Slack WV. Profile of women practicing breast self-examination. JAMA. 1983;249:488-491.
28. Reports of the Working Group to Review the National Cancer Institute-American Cancer Society Breast Cancer Detection Demonstration Project. J Natl Cancer Inst. 1979;62:639-709.
29. Miller AB, Baines CJ, Turnball C. The role of the nurse examiner in the National Breast Screening Study. Can J Public Health. 1991;82:162-167.
30. Campbell HS, Fletcher SW, Lin S, Pilgrim CA, Morgan TM. Improving physicians' and nurses' clinical breast examination. Am J Prev Med. 1991; 7:1-8.
31. Fletcher SW, O'Malley MS, Bunce LA. Physicians' abilities to detect lumps in silicone breast models. JAMA. 1985;253:2224-2228.
32. Hoskins KF, Stopfer JE, Calzone KA, et al. Assessment and counseling for women with a family history of breast cancer: a guide for clinicians. JAMA. 1995;273:577-585.
33. Lynch HT, Watson P, Conway TA, et al. DNA screening for breast/ovarian cancer susceptibility based on linked markers: a family study. Arch Intern Med. 1993;153:1979-1987.
34. Vasen HFA. Screening in breast cancer families: is it useful? Ann Med. 1994;26:185-190.
35. Mettler FA, Upton AC, Kelsey CA, Ashby RN, Rosenberg RD, Linver MN. Benefits versus risks from mammography. Cancer. 1996;77:903-909.
36. Kerlikowske K, Grady D, Rubin SM, Sandrock C, Ernster VL. Efficacy of screening mammography: a meta-analysis. JAMA. 1995;273:149-154.
37. Kopans DB. Mammography screening and the controversy concerning women aged 40-49. Radiol Clin North Am. 1995;33:1273-1290.
38. Fletcher SW. Why question screening mammography for women in their forties? Radiol Clin North Am. 1995;33:1259-1271.
39. Fletcher SW, Black W, Harris R, et al. Report of the international workshop on screening for breast cancer. J Natl Cancer Inst. 1995;85:1644-1656.
40. Mettlin C, Smart CR. Breast cancer detection guidelines for women aged 40-49 years. CA Cancer J Clin. 1994;44:248-255.
41. Evans JS, Wennberg JE, McNeil BJ. The influence of diagnostic radiography on the incidence of breast cancer and leukemia. N Engl J Med. 1986; 315:810-815.
42. John EM, Kelsey JL. Radiation and other environmental exposures and breast cancer. Epidemiol Rev. 1993;15:157-162.
43. NIH Consensus Development Panel on Ovarian Cancer. Ovarian cancer: screening, treatment, and follow-up. JAMA. 1995;273:491-497.
44. Jacobs I, Bast RC Jr. The CA-125 tumor-associated antigen. Hum Reprod. 1989;4:1-12.
45. Gargano G, Correale M, Abbate I, et al. The role of tumor markers in ovarian cancer. Clin Exp Obstet Gynecol. 1990;17:23-29.
46. Niloff JM. Tumor markers. In: Hoskins WJ, Ferez CA, Young RC, eds. Principles and Practice of Gynecologic Oncology. Philadelphia, Pa: JB Lippincott; 1992:137-150.
47. Helzlsouer KJ, Bush TL, Alberg AJ, Bass KM, Zacor H, Comstock GW. Prospective study of serum CA-125 levels as markers of ovarian cancer. JAMA. 1993;269:1123-1126.
48. Muto MG, Cramer DW, Brown DL, et al. Screening for ovarian cancer. Gynecol Oncol. 1993;51:12-20.
49. Zurawski R, Orjaseter H, Anderson A, et al. Elevated serum CA-125 levels prior to diagnosis of ovarian neoplasia. Int J Cancer. 1988;42:677-680.
50. Vasilev S, Schlaerth J, Campeau J, et al. Serum CA-125 levels in preoperative evaluation of pelvic masses. Obstet Gynecol. 1988;71:751-756.
51. Skates SJ, Feng-Ji X, Yin-Hua Y, et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer. 1995;76: 2004-2010.
52. Einhorn N, Sjovall K, Knapp RC, et al. Prospective evaluation of serum CA-125 levels for the early detection of ovarian cancer. Obstet Gynecol. 1992;80:14-18.
53. Campbell S, Bhan V, Royston P, et al. Transabdominal ultrasound screening for early ovarian cancer. BMJ. 1989;299:1363-1367.
54. Jacobs I, Stabile I, Bridges J, et al. Multimodal approach to screening for ovarian cancer. Lancet. 1988;1:268-271.
55. Higgins R, van Nagell J, Donaldson E, et al. Transvaginal sonography as a screening method for ovarian cancer. Gynecol Oncol. 1989;34:402-406.
56. van Nagell J, Higgins R, Donaldson E, et al. Transvaginal sonography as a screening method for ovarian cancer. Cancer. 1990;65:573-577.
57. van Nagell J, DePriest P, Puls L, et al. Ovarian cancer screening in asymptomatic postmenopausal women by transvaginal sonography. Cancer. 1991; 68:458-462.
58. Daly MB. The epidemiology of ovarian cancer. Hematol Oncol Clin North Am. 1992;6:729-738.
59. Bourne T, Whitehead M, Campbell S, et al. Ultrasound screening for familial ovarian cancer. Gynecol Oncol. 1991;43:92-97.
60. Kurjak A, Zalud I, Alfirevic Z. Evaluation of adnexal masses with transvaginal color ultrasound. J Ultrasound Med. 1991;10:295-297.
61. Jacobs I, Davies AP, Bridges J, et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ. 1993;306:1030-1034.
62. Kramer BS, Gohagan J, Prorok PC, Smart C. A National Cancer Institute-sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers. Cancer. 1993;71:589-593.
63. Mettlin C, Jones G, Averette H, Gusberg SB, Murphy GP. Defining and updating the American Cancer Society Guidelines for the cancer-related checkup. CA Cancer J Clin. 1993;43:42-46.
64. Littrup PJ. Prostate cancer screening: appropriate choices? Cancer. 1994;74:2016-2022.
65. Woolf SH. Screening for prostate cancer with prostate-specific antigen: an examination of the evidence. N Engl J Med. 1995;333:1401-1405.
66. Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994;330: 242-248.
67. Johansson JE, Adami H-O, Andersson SO, Bergstrom R, Holmberg L, Krusemo VB. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA. 1992;267:2191-2196.
68. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS. Screening for prostate cancer. JAMA. 1994;272:773-780.
69. Kramer BS, Brown ML, Prorok PC, et al. Prostate cancer screening: what we know and what we need to know. Ann Intern Med. 1993;119:914-923.
70. Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med. 1992;326:653-657.
71. Fleischer DE, Goldberg SB, Browning TH, et al. Detection and surveillance of colorectal cancer. JAMA. 1989;261:580-585.
72. National Cancer Institute. Working Guidelines for Early Cancer Detection: Rationale and Supporting Evidence to Decrease Mortality. Bethesda, Md: National Cancer Institute; 1987.
73. Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS. Effect of fecal occult blood testing on mortality from colorectal cancer: a case-control study. Ann Intern Med. 1993;118:1-6.
74. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med. 1993;328:1365-1367.
75. Levin B, Murphy GP. Revision in American Cancer Society recommendations for the early detection of colorectal cancer. CA Cancer J Clin. 1992;42:296-299.
76. Goodnight JE, Quagliana JM, Morton DL. Failure of subcutaneous mastectomy to prevent the development of breast cancer. J Surg Oncol. 1984; 26:198-201.
77. Kieback DG, Kieback CC. Advanced breast cancer after subcutaneous mastectomy and immediate prosthetic reconstruction for benign breast disease. Breast Cancer Res Treat. 1986;7:119-120.
78. Mies C. Recurrent secretory carcinoma in residual mammary tissue after mastectomy. Am J Surg Pathol 1993;17:715-721.
79. Eldar S, Meguid MM, Beatty JD. Cancer of the breast after prophylactic subcutaneous mastectomy. Am J Surg. 1984;148:692-693.
80. Pennisi VR, Capozzi A. Subcutaneous mastectomy data. Aesthetic Plast Surg. 1989;13:15-21.
81. Bilimoria MM, Morrow M. The woman at increased risk for breast cancer: evaluation and management strategies. CA Cancer J Clin. 1995;45: 263-278.
82. Humphrey LJ. Subcutaneous mastectomy is not a prophylaxis against carcinoma of the breast: opinion or knowledge? Am J Surg. 1983;145:311-312.
83. Slade CL. Subcutaneous mastectomy. Plast Reconstr Surg. 1984;73:84-90.
84. Goldman LD, Goldwyn RM. Some anatomical considerations of subcutaneous mastectomy. Plast Reconstr Surg. 1973;51:501-505.
85. Hicken NF. Mastectomy. Arch Surg. 1940;40: 6-14.
86. Woods JE. Breast reconstruction: current state of the art. Mayo Clin Proc. 1986;61:579-585.
87. Wapnir IL, Rabinowitz B, Greco RS. A reappraisal of prophylactic mastectomy. Surg Gynecol Obstet. 1990;171:171-184.
88. Hyland WT. Subcutaneous mastectomy. Surg Clin North Am. 1985;65:373-381.
89. Snyderman RK. Prophylactic mastectomy: pros and cons. Cancer. 1984;53:803-808.
90. Rubin LR. Prophylactic mastectomy with immediate reconstruction for the high-risk woman. Clin Plast Surg. 1984;11:369-381.
91. Temple WJ, Lindsay RL, Magi E, Urbanski SJ. Technical considerations for prophylactic mastectomy in patients at high risk for breast cancer. Am J Surg. 1991;161:413-415.
92. Piver MS, Jishi MF, Tsukada Y, Nava G. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. Cancer. 1993;71:2651-2655.
93. Struewing JP, Watson P, Easton DF. Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr. 1995;17: 33-35.
94. Tobacman JK, Tucker MA, Kase R. Intraabdominal carcinomatosis after prophylactic oophorectomy in ovarian cancer prone families. Lancet. 1982;2:795-797.
95. Nguyen HN, Averette HE, Janicek M. Ovarian carcinoma. Cancer, 1994;74:545-555.
96. Kerlikowske K, Brown JS, Grady DG. Should women with familial ovarian cancer undergo prophylactic oophorectomy? Obstet Gynecol. 1992;80: 700-707.
97. Schurman, AG, van den Brandt P, Goldbohm RA. Exogenous hormone use and the risk of post menopausal breast cancer. Cancer Causes Control. 1995;6:416-424.
98. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in post-menopausal women. N Engl J Med. 1995;332:1589-1592.
99. Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA. 1991; 265:1985-1990.
100. Grady D, Rubin S, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in post-menopausal women. Ann Intern Med. 1992;117:1016-1037.
101. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA. 1995;274:137-142.
102. Newcomb PA, Longnecker MP, Stover BE, et al. Long-term hormonal replacement therapy and risk of breast cancer in post-menopausal women. Am J Epidemiol. 1995;142:788-795.
103. Division of Cancer Prevention and Control. Clinical Trials of Hormone Replacement Therapy in Patients With a History of Breast Cancer: Minutes of a Working Group. Bethesda, Md: National Cancer Institute; 1993.
104. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer. Am J Obstet Gynecol. 1993;168:1473-1480.
105. Gorsky R, Koplan J, Peterson H, Thacker S. Relative risks and benefits of long-term estrogen replacement therapy: a decision analysis. Obstet Gynecol. 1994;83:161-166.
106. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives. Lancet. 1996;347:1713-1727.
107. Hankinson SE, Colditz GA, Hunter DJ, Spencer TL, Rosner B, Stampfer MJ. A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol. 1992;80:708-714.
108. Gross TP, Schlesselman JJ. The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer. Obstet Gynecol. 1994; 83:419-424.
109. Hartge P, Whittemore AS, Itnyre J, McGowan L, Cramer D. Rates and risks of ovarian cancer in subgroups of white women in the United States. Obstet Gynecol. 1994;84:760-764.
110. Piver MS, Baker TR, Jishi MF, et al. Familial ovarian cancer. Cancer. 1993;72(suppl 2):582-588.
111. O'Shaughnessy JA. Chemoprevention of breast cancer. JAMA. 1996;275:1349-1353.
112. van Leeuwen FE, Benraadt J, Coeberg JW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet. 1994;343:448-452.
113. Daling JR, Malone KE, Voigt LF, White E, Weiss N. Risk of breast cancer among young women. J Natl Cancer Inst. 1994;86:1584-1592.
114. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev. 1993;15:37-47.
115. Prentice R, Sheppard L. Dietary fat and cancer. Cancer Causes Control. 1990;1:81-97.
116. Rosenberg L, Metzger LS, Palmer JR. Alcohol consumption and risk of breast cancer. Epidemiol Rev. 1993;15:133-144.
117. Hunter DJ, Willett WC. Diet, body size, and breast cancer. Epidemiol Rev. 1993;15:110-132.
118. McTiernan A, Stanford J, Weiss NS, Daling JR. Occurrence of breast cancer in relation to recreational exercise in women age 50-64 years. Epidemiology. 1996;7:598-604.
119. Bernstein L, Henderson BE, Hanisch R, et al. Physical exercise and reduced risk of breast cancer in young women. J Natl Cancer Inst. 1994;86:1403-1408.
120. NCI Cancer Genetics Network promises to widen testing, information access. Scientist. July 22, 1996;10:1,8.